Milestone Pharmaceuticals... (MIST)
Milestone Pharmaceuticals Statistics
Share Statistics
Milestone Pharmaceuticals has 53.35M shares outstanding. The number of shares has increased by 0.18% in one year.
| Shares Outstanding | 53.35M |
| Shares Change (YoY) | 0.18% |
| Shares Change (QoQ) | 0.05% |
| Owned by Institutions (%) | 37.09% |
| Shares Floating | 50.79M |
| Failed to Deliver (FTD) Shares | 3.44K |
| FTD / Avg. Volume | 0.15% |
Short Selling Information
The latest short interest is 454.79K, so 0.85% of the outstanding shares have been sold short.
| Short Interest | 454.79K |
| Short % of Shares Out | 0.85% |
| Short % of Float | 0.9% |
| Short Ratio (days to cover) | 2.46 |
Valuation Ratios
The PE ratio is 0 and the forward PE ratio is -2.44. Milestone Pharmaceuticals's PEG ratio is 0.
| PE Ratio | 0 |
| Forward PE | -2.44 |
| PS Ratio | 0 |
| Forward PS | 0.1 |
| PB Ratio | 11.17 |
| P/FCF Ratio | -5.09 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Milestone Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.1, with a Debt / Equity ratio of 4.17.
| Current Ratio | 9.1 |
| Quick Ratio | 9.1 |
| Debt / Equity | 4.17 |
| Debt / EBITDA | -1.3 |
| Debt / FCF | -1.9 |
| Interest Coverage | 11.76 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $0 |
| Employee Count | 33 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -57.14% in the last 52 weeks. The beta is 1.38, so Milestone Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 1.38 |
| 52-Week Price Change | -57.14% |
| 50-Day Moving Average | 1.89 |
| 200-Day Moving Average | 1.68 |
| Relative Strength Index (RSI) | 29.8 |
| Average Volume (20 Days) | 2.23M |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -42.1M |
| Net Income | 0 |
| EBITDA | -42.1M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.67 |
Balance Sheet
The company has 25.31M in cash and 54.8M in debt, giving a net cash position of -29.48M.
| Cash & Cash Equivalents | 25.31M |
| Total Debt | 54.8M |
| Net Cash | -29.48M |
| Retained Earnings | -367.55M |
| Total Assets | 75.5M |
| Working Capital | 65.8M |
Cash Flow
In the last 12 months, operating cash flow was -28.85M and capital expenditures 0, giving a free cash flow of -28.85M.
| Operating Cash Flow | -28.85M |
| Capital Expenditures | 0 |
| Free Cash Flow | -28.85M |
| FCF Per Share | -0.46 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
MIST does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for MIST is $9.5, which is 1166.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $9.5 |
| Price Target Difference | 1166.7% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Scores
| Altman Z-Score | -7.09 |
| Piotroski F-Score | 2 |